Xospata
Chemical Name | gilteritinib |
Dosage Form | Tablet (oral; 40 mg) |
Drug Class | Kinase inhibitors |
System | Blood |
Company | Astellas Pharma |
Approval Year | 2018 |
Indication
- Indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test